Substantial data support major roles for bone-derived TGF-␤ 1 and tumor-derived parathyroid hormone-related protein (PTHrP) in the vicious cycle of local bone destruction that characterizes osteolytic metastases. Tumor-produced PTHrP stimulates osteoclastic bone resorption to result in the bone destruction associated with breast cancer metastases (1, 2). Neutralizing antibodies to PTHrP not only decreased osteoclastic bone resorption but also inhibited the development of metastases to bone by the human breast cancer cell line, MDA-MB-231 (3). TGF-␤, stored in bone matrix (4) and released locally in active form during osteoclastic resorption (5), stimulates PTHrP production by tumor cells (6 -8). A dominantnegative TGF-␤ type II receptor (T␤RII⌬cyt) stably expressed in the MDA-MB-231 breast cancer line rendered the cells unresponsive to TGF-␤ and inhibited TGF-␤-induced PTHrP secretion and the development of bone metastases in a mouse model. This dominant-negative type II blockade was reversed by a constitutively active TGF-␤ type I receptor (T␤RI(T204D)). Furthermore, transfection of the cDNA for PTHrP into the dominant-negative MDA-MB-231 line also increased PTHrP production and accelerated bone metastases (9). These published data establish that TGF-␤ in bone can promote osteolysis by increasing PTHrP secretion from breast cancer cells. They do not, however, exclude contributions from other TGF-␤-responsive tumor factors. Here we demonstrate that PTHrP is the central mediator of TGF-␤-induced osteolytic metastasis. We also show that TGF-␤ increases PTHrP secretion from MDA-MB-231 cells by signaling through both Smad and p38 MAP kinase pathways.
Substantial data support major roles for bone-derived TGF-␤ 1 and tumor-derived parathyroid hormone-related protein (PTHrP) in the vicious cycle of local bone destruction that characterizes osteolytic metastases. Tumor-produced PTHrP stimulates osteoclastic bone resorption to result in the bone destruction associated with breast cancer metastases (1, 2) . Neutralizing antibodies to PTHrP not only decreased osteoclastic bone resorption but also inhibited the development of metastases to bone by the human breast cancer cell line, MDA-MB-231 (3). TGF-␤, stored in bone matrix (4) and released locally in active form during osteoclastic resorption (5), stimulates PTHrP production by tumor cells (6 -8) . A dominantnegative TGF-␤ type II receptor (T␤RII⌬cyt) stably expressed in the MDA-MB-231 breast cancer line rendered the cells unresponsive to TGF-␤ and inhibited TGF-␤-induced PTHrP secretion and the development of bone metastases in a mouse model. This dominant-negative type II blockade was reversed by a constitutively active TGF-␤ type I receptor (T␤RI(T204D)). Furthermore, transfection of the cDNA for PTHrP into the dominant-negative MDA-MB-231 line also increased PTHrP production and accelerated bone metastases (9) . These published data establish that TGF-␤ in bone can promote osteolysis by increasing PTHrP secretion from breast cancer cells. They do not, however, exclude contributions from other TGF-␤-responsive tumor factors. Here we demonstrate that PTHrP is the central mediator of TGF-␤-induced osteolytic metastasis. We also show that TGF-␤ increases PTHrP secretion from MDA-MB-231 cells by signaling through both Smad and p38 MAP kinase pathways. First, to determine whether PTHrP is the major mediator of TGF-␤-induced osteolysis, mice were inoculated with an MDA-MB-231 clonal line overexpressing the constitutively active type I TGF-␤ receptor, T␤RI(T204D), and treated with neutralizing PTHrP antibody or control IgG. The mice treated with PTHrP antibody had a significantly lower tumor burden than the control mice, suggesting that the major downstream effector of TGF-␤ in the development and progression of bone metastases was PTHrP.
TGF-␤ increases PTHrP expression by stabilizing mRNA as well as by transcriptional mechanisms (6 -8, 10 -12) . The signaling pathways through which TGF-␤ increases PTHrP secretion in breast cancer cells have not been defined, although intracellular mediators known as Smads are indispensable for many of the responses to TGF-␤ (12) (13) (14) (15) . However, there is also accumulating evidence that TGF-␤ signals through other path-ways (16 -18) . TGF-␤ activates MAP kinase pathway components Ras, ERK1/2, and JNKs (19 -27) . TGF-␤-activated kinase 1 (TAK1) and its upstream activator TAK1-binding protein mediate some responses to TGF-␤ family members (16, 17) . Activation by TGF-␤ of p38 MAP kinase, which is downstream of TAK1, has also been reported (28, 29) . Recently, MAP kinase kinase-independent activation of p38␣ by a TAK1-binding protein-dependent mechanism was demonstrated (30) .
To examine the signaling pathways by which the TGF-␤ increases the PTHrP production, wild-type and dominant-negative Smad2, Smad3, and Smad4 were stably overexpressed in MDA-MB-231 breast cancer cells, and the changes in PTHrP production were measured. The data supported both Smaddependent and independent mechanism for the TGF-␤ stimulation of PTHrP production by breast cancer cells. Specific protein kinase inhibitors were used to determine the Smadindependent signaling of TGF-␤ to increase PTHrP production. This study indicated that the MAP kinase pathway, and specifically p38 MAP kinase, is a major component of this Smad-independent signaling by TGF-␤ and provides new molecular targets for anti-osteolytic therapy.
EXPERIMENTAL PROCEDURES

Cell Lines and Culture
MDA-MB-231 cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% heat-inactivated fetal calf serum (HyClone Laboratories, Logan, UT), 1% penicillin/streptomycin (Invitrogen), and 1% nonessential amino acids (Invitrogen).
Plasmid Constructs, Transfections, and Production of Stable Cell Lines
The Smad2 wild-type (pcDNA3-FLAG-MADR2) and dominant-negative (pcDNA3-FLAG-MADR2(3S-A)) cDNA expression plasmids were provided by Drs. Wrana and Attisano (University of Toronto, Toronto, Canada) (31); Smad4 wild-type (pCMV5-DPC4-HA), Smad3 wild-type (pCS2-FLAG-Smad3), Smad3 dominant-negative (pCS2-FLAGSmad3(3S-A)), and Smad4 dominant-negative (pCMV5-FLAG-DPC4 (1-514)) plasmids were provided by Dr. Massagué, (Memorial SloanKettering Cancer Center, New York, NY) (32) , and the dominantnegative pcDNA3-FLAG-Smad3D407E by Dr. Kato, Tokyo, Japan (33) . The Smad wild-type and dominant-negative cDNAs were recloned into the pcDNA3 expression vector (Invitrogen). The Smad plasmids and pcDNA3 (empty vector) were transfected into MDA-MB-231 cells using LipofectAMINE PLUS TM reagent (Invitrogen). Single clones were isolated by limiting dilution in the presence of neomycin analogue G418 (Sigma). The clones were assessed by transient transfection with the TGF-␤-responsive plasminogen activator inhibitor promoter linked to firefly luciferase (3TP-lux), as well as PTHrP production in response to 5 ng/ml recombinant human TGF-␤1 (R & D Systems Inc.) in serumfree Dulbecco's modified Eagle's medium after 24 h of incubation. More than 50 clones were characterized for each construct.
The MDA-MB-231 clone overexpressing dominant-negative TGF-␤ type II receptor (T␤RII⌬cyt), which is truncated at the intracytoplasmic domain (34), was constructed as described previously (9) . This clone, MDA-MB-231/T␤RII⌬cyt, is unresponsive to TGF-␤. Stable expression of a constitutively active TGF-␤ type I receptor (T␤RI(T204D)) (35) into MDA-MB-231/T␤RII⌬cyt reversed the dominant-negative TGF-␤ blockade. This stable clone, MDA-MB-231/T␤RII⌬cyt ϩ T␤RI(T204D), demonstrated constitutive TGF-␤ activity, even in the absence of ligand (9) .
Inhibitor Studies
The inhibitors were dissolved in Me 2 SO (cell culture grade; Sigma) and used in the following concentrations: wortmannin (20 M), herbimycin A (35 nM), KT5720 (100 nM), KT5823 (150 nM), SB203580 (10 M), SB202190 (10 M), and PD98059 (20 M). All of the inhibitors except wortmannin (Sigma) were obtained form Calbiochem. The inhibitors diluted in normal growth medium were added to wells containing confluent MDA-MB-231 cells and incubated for 3 h. TGF-␤ (5 ng/ml) was added to serum-free medium containing the respective inhibitors and incubated for 24 h, after which time the conditioned media were collected and the cells were counted. The samples were stored at Ϫ80°C until measured. Me 2 SO (0.05% v/v) diluted in medium was used as a negative control.
The optimal inhibitor concentration and incubation time for MAP kinase inhibitors SB203580, SB202190, and PD98059 were determined by time course and dose-response studies. Concentrations for p38 inhibitors SB203580 and SB202190 (1, 5, 10, 20 , and 40 M) and for MEK inhibitor PD98059 (2, 10, 20, 40 , and 80 M) were tested. The concentrations of 10 and 20 M were selected for p38 inhibitors and MEK inhibitor, respectively, based on the capacity to inhibit PTHrP production without affecting cell viability. Subsequently, incubation times of 6, 12, 24, 30 , and 48 h after 3 h of preincubation were used to determine the optimal inhibitor incubation time without affecting cell viability. The results indicated that the 24-h incubation time was optimal for all of the MAP kinase inhibitors used.
Animals
The animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Female nude (BALB/c) mice 4 weeks of age were housed in laminar flow isolated hoods. Water supplemented with vitamin K and autoclaved mouse chow were provided ad libitum. Whole blood samples for ionized calcium concentration were obtained by retro-orbital puncture under metofane anesthesia, and the radiographs were taken under mouse mixture (30% ketamine and 20% xylazine in 0.9% NaCl). Tumor inoculation into the left cardiac ventricle was performed as described previously (3).
Experimental Protocols: Bone Metastases
The mice were inoculated with a tumor cell suspension of clonal MDA-MB-231/T␤RII⌬cyt ϩ T␤RI(T204D) cells into the left cardiac ventricle on day 0, after base-line radiographs, body weight, and blood Ca 2ϩ were determined. The mice were treated with neutralizing PTHrP mAb directed against PTHrP(1-34) (antibody-producing hybridoma, 3F5, obtained from Dr. T. J. Martin, St. Vincent's Institute, Melbourne, Australia) or isotype matched control IgG (Sigma) (n ϭ 8/group; 1 mg subcutaneously, at the time of tumor inoculation and 1 week later). Ca 2ϩ , body weight, and radiographs were monitored weekly for 6 weeks, at which time the mice were sacrificed. All of the bones and soft tissues were fixed in formalin for histological analysis. The radiographs were analyzed as described later in this paper. Neutralizing PTHrP mAb was produced as ascitic fluid in BALB/c mice primed with Pristane (2,6,10,14-tetramethly pentadecane; Sigma) and purified by protein G-agarose chromatography (Amersham Biosciences).
In Vitro Analytical Methods
3TP-lux in Response to TGF-␤-
Response to TGF-␤ was measured by transient transfection of the 3TP-lux reporter construct, which contains three copies of a TGF-␤-responsive element from the plasminogen activator inhibitor-1 promoter linked to a firefly luciferase-coding sequence. The 3TP-lux reporter is activated by Smad2, Smad3, and Smad4 (31, 32, 36, 37) . Co-transfected pRL-TK (Promega, Madison, WI) was used as an internal control reporter expressing Renilla luciferase. The Renilla and firefly luciferase activity in cell lysates was measured using the Dual-Luciferase reporter assay system (Promega) and a Turner TD-20e luminometer (Turner Designs Inc., Sunnyvale, CA).
PTHrP Assay-PTHrP concentrations were measured in 24-h conditioned media using a two-site immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA) as reported previously (3). The standard curve was generated by using Dulbecco's modified Eagle's medium as a standard diluent; 0.3pmol/l was the limit of detection.
p38 MAP Kinase Phosphorylation-MDA-MB-231 breast cancer cells were cultured on Petri plates without or with 5 ng/ml of TGF-␤ for various times (0, 10, 20, and 30 min and 1, 2, 4, 6, 8, 24, 48, and 72 h). After incubation the cells were lysed using cell lysis buffer (New England Biolabs, Beverly, MA) according to the manufacturer's suggestions. Western blotting was performed according to the manufacturer's directions (New England Biolabs) using phospho-p38 MAP kinase (Thr 180 /Tyr 182 ) and p38 MAP kinase-specific antibodies to detect the phosphorylated and total p38 MAP kinase. Relative phosphorylation was determined using intensity values quantitated with a Kodak Digital Science TM electrophoresis documentation and analysis system 120 (Eastman Kodak Co.).
In Vivo Analytical Methods
Ca
2ϩ Measurement-Ca 2ϩ concentrations were measured in whole blood using a Ciba Corning 634 ISE Ca 2ϩ /pH analyzer (Corning Medical and Scientific, Medfield, MA) as described previously (3).
Radiographs and Measurement for Osteolytic Lesion Area-
The animals were x-rayed using a 43855A x-ray system (Faxitron, Buffalo Grove, IL) as described previously (3) . All of the radiographs were evaluated without knowledge of the treatment groups. Quantitation of 514) ) or dominant-negative TGF-␤ type II receptor (T␤RII⌬cyt) clones were transiently transfected with a Smad/TGF-␤-responsive plasminogen activator inhibitor promoter derivative linked to firefly luciferase (3TP-lux) and pRL-TK vector. The Renilla and firefly luciferase activity in cell lysates was measured using a Dual-Luciferase reporter assay system. MDA-MB-231 clone expressing empty vector (pCDNA3) was used as a control. ***, p Ͻ 0.001; NS, not significant. lesion area was performed using image analysis software (Java, Jandel Video Analysis; Jandel Scientific, Corte Madera, CA).
Bone Histology and Histomorphometry-Forelimb and hind limb bones were removed from mice at the time of sacrifice, fixed in 10% buffered formalin, decalcified in 14% EDTA, and embedded in paraffin. The sections were stained with hematoxylin, eosin, orange G, and phloxine. Total tumor area and osteoclast number/mm of tumor/bone interface were measured in midsections of tibiae and femora without knowledge of experimental groups. Histomorphometric analysis was performed using OsteoMeasure System program (Osteometrics Inc., Atlanta, GA).
Statistical Methods
The results are expressed as the means Ϯ S.E. The data were analyzed by analysis of variance followed by Tukey-Kramer post-test. p Ͻ 0.05 was considered statistically significant.
RESULTS
PTHrP Is the Central Effector of TGF-␤ in the Pathogenesis of
Osteolytic Bone Metastases-Six weeks after tumor inoculation with the MDA-MB-231 stable clone expressing the constitutively active TGF-␤ type I receptor (MDA-MB-231/T␤RII⌬cyt ϩ T␤RI(T204D)), the number and the area of osteolytic lesions were significantly less in mice treated with PTHrP mAb compared with those treated with control IgG (Fig. 1, A and B) . The tumor area was less, and osteoclasts were fewer in tumorbearing mice treated with PTHrP mAb (Fig. 1, C and D) . The body weights were greater in mice treated with PTHrP mAb compared with the control IgG (21.7 Ϯ 0.7 g versus 17.7 Ϯ 0.9 g; p ϭ 0.009).
Overexpression of Wild-type and Dominant-negative Smads in MDA-MB-231
Cells-To test whether the major effect of TGF-␤ on PTHrP production is via the Smad proteins, we stably expressed wild-type and dominant-negative mutants of Smad2, Smad3, and Smad4 in MDA-MB-231. Wild-type Smad2, Smad3, and Smad4 clones, which had enhanced responses to TGF-␤, and dominant-negative Smad clones, which had reduced response to TGF-␤ in the 3TP-lux reporter assay, were further characterized. Fig. 2 demonstrates that MDA-MB-231 stable clones that express dominant-negative Smad2, Smad3, or Smad4 did not respond to TGF-␤ in the 3TP-lux reporter assay.
TGF-␤-induced PTHrP Production Is Only Partially Smaddependent-Stable
MDA-MB-231 clones that express wild-type or dominant-negative Smad forms were characterized for PTHrP production in response to TGF-␤ using a two-site PTHrP immunoradiometric assay (Fig. 3) . Compared with parental cells and empty vector controls, the MDA-MB-231/ T␤RII⌬cyt cell line was unresponsive to TGF-␤, as reported previously (9) . In contrast, overexpression of the dominantnegative Smads (Smad2(3S-A), Smad3(3S-A), Smad3(D407E), or Smad4(1-514)) failed to completely suppress TGF-␤-stimulated PTHrP secretion by MDA-MB-231 cells. On the other hand, overexpression of wild-type Smad2, Smad3, and Smad4 enhanced PTHrP production in response to TGF-␤. These data suggest that TGF-␤ signaling to induce PTHrP production is mediated only partially through the Smad pathway.
MAP Kinase Pathway Is a Major Component of the Smadindependent Signaling by TGF-␤-
The data suggested that both Smad-dependent and -independent pathways mediated the effect of TGF-␤ to stimulate PTHrP production by MDA-MB-231 breast cancer cells. We investigated the Smad-independent pathways by treating parental MDA-MB-231 with specific signaling pathway inhibitors. Protein kinase A (KT5720), protein kinase G (KT5823), tyrosine kinase (herbimycin A), and phosphatidylinositol 3-kinase (wortmannin) inhibitors did not affect basal or TGF-␤-induced PTHrP secretion (Fig. 4) . However, the p38 MAP kinase inhibitors, SB203580 and SB202190, and the MEK1/2 inhibitor, PD98059, significantly reduced both basal and TGF-␤-stimulated PTHrP production dose-dependently (Fig. 4) . Therefore, these inhibitors were tested in the context of the Smad dominant-negative blockade. In empty vector MDA-MB-231 clones, TGF-␤-stimulated PTHrP was effectively decreased by both p38 inhibitors; SB202190 was more potent (Fig. 5A) . The reduction of TGF-␤-stimulated PTHrP production by the MEK inhibitor, PD98059, was likely due to decreased basal PTHrP production because the ratio of TGF-␤-stimulated PTHrP to untreated was similar to the control. The cells expressing the dominant-negative TGF-␤ type II receptor (MDA-MB-231/T␤RII⌬cyt) did not respond to TGF-␤ and secreted a low amount of PTHrP that was not affected by either p38 or MEK1/2 inhibitors (Fig. 5B) . p38 inhibition by SB202190 significantly reduced basal and TGF-␤-induced PTHrP production by an MDA-MB-231 clone that expressed the constitutively active TGF-␤ type I receptor (T␤RII⌬cyt ϩ T␤RI(T204D)), whereas MEK inhibition by PD98059 reduced the basal PTHrP synthesis (Fig. 5B, inset) .
The effects of MAP kinase inhibition on PTHrP production by Smad dominant-negative clones are shown in Fig. 5 (C-F) . In the presence of Smad2 dominant-negative blockade, p38 inhibition decreased the basal and TGF-␤-induced PTHrP production. MEK inhibition reduced basal PTHrP production, but the ratio of TGF-␤-stimulated PTHrP to control was similar to no inhibition (Fig. 5C ). The combination of p38 inhibition and Smad2 dominant-negative blockade totally inhibited the TGF-␤ induction of PTHrP, comparable with that observed in the dominant-negative type II TGF-␤ receptor. Similar results were obtained with the Smad3 and Smad4 dominant-negative clones (Fig. 5, D-F) . However, the clone that expressed the dominant-negative Smad3(D407E) displayed less responsiveness to TGF-␤ in the presence of p38 inhibition than the Smad3(3S-A) clone (Fig. 5E) .
The data suggested that TGF-␤ signals via p38 MAP kinase to induce PTHrP production in MDA-231 cells. We confirmed the involvement of p38 MAP kinase in TGF-␤-signaling in parental MDA-MB-231 cells using Western blotting and antibodies specific for nonphosphorylated and phosphorylated p38 MAP kinase. The relative phosphorylation of p38 MAP kinase was increased in MDA-MB-231 cells treated with 5 ng/ml of TGF-␤ compared with control. The TGF-␤-induced phosphorylation of p38 MAP kinase occurred as early as 10 min posttreatment and peaked at 1 h with a 5.5-fold increase. (Fig. 6 ).
DISCUSSION
The role of TGF-␤ in malignancy is multifunctional (38, 39) . TGF-␤ inhibits growth of epithelial and some tumor cells. Certain carcinomas have inactivated or deleted TGF-␤ receptors or Smad proteins (40) . In contrast, TGF-␤ can also promote invasion and metastases (41) (42) (43) (44) . Our previous studies support an additional role for TGF-␤ in malignancy to promote breast cancer osteolysis by stimulating tumor production PTHrP (9) . Expression of a dominant-negative type II TGF-␤ receptor in MDA-MB-231 cells blocked TGF-␤-stimulated PTHrP in vitro and the development and progression of bone metastases in vivo. This was reversed by overexpression of either a constitutively active type I TGF-␤ receptor or PTHrP. These experiments suggested that the effects of TGF-␤ to promote breast cancer metastases to bone were mediated by tumor production of PTHrP, but they did not exclude other effects of TGF-␤. The experiments presented here provide evidence that the central effector of TGF-␤ on the development and progression of bone metastases is PTHrP. Mice inoculated with an MDA-MB-231 clonal line that expressed the constitutively active type I TGF-␤ receptor, T␤RI(T204D), had extensive osteolysis that was prevented by treatment with a neutralizing monoclonal antibody directed against PTHrP (1-34) .
How does TGF-␤ mediate its effects on tumor cells in the bone microenvironment to promote osteolysis? TGF-␤ released from bone matrix as a consequence of osteoclastic bone resorption (5) binds to the type II TGF-␤ serine-threonine kinase receptor on the surface of tumor cells. This complex recruits and phosphorylates the type I receptor. The heterotetrameric TGF-␤ receptor complex in turn phosphorylates the receptorregulated Smad2 and Smad3, which then form hetero-oligomers with Smad4 that translocate into the nucleus, where they assemble with transcription complexes and regulate the expression of target genes.
Overexpression of receptor-regulated Smad2 and Smad3 and the co-Smad 4 increased TGF-␤ responsiveness in various cell lines (33, (45) (46) (47) (48) (49) . Our results are consistent with these findings in that the overexpression of wild-type Smads increased the TGF-␤-stimulated PTHrP production in MDA-MB-231 cells. Smad4(1-514) . The clonal lines were grown to near confluence in 48-well plates, washed, and treated with inhibitors (10 M SB203580, 10 M SB202190, and 20 M PD98059) as described in Fig. 4 . The PTHrP concentrations in conditioned media were corrected for cell number. The values represent the means Ϯ S.E. (n ϭ 3/group). ***, the statistical difference between the TGF-␤-treated and untreated control; ࡗࡗࡗ, represent the statistical difference between the inhibitor and Me 2 SO control (for *** and ࡗࡗࡗ, p Ͻ 0.001; for ** and ࡗࡗ, p Ͻ 0.01; for * and ࡗ, p Ͻ 0.001). NS, not significant.
C, Smad2(3S-A). D, Smad3(3S-A). E, Smad3(D407E). F,
the Smad mutant constructs may not have functioned as complete dominant-negatives. This possibility is unlikely because the efficacy of the Smad dominant-negative constructs has been widely demonstrated in transient transfection assays (31) (32) (33) . Our results show that the stable Smad dominant-negative clones were not responsive to TGF-␤ in the 3TP-lux reporter assay. Thus, the dominant-negative constructs expressed in these cell lines are sufficient completely to block TGF-␤ responsiveness through the Smad pathway. Second, expression of the dominant-negative Smad could have induced compensatory expression of endogenous Smad proteins. This explanation might account for the situation with Smad2 and Smad3 dominantnegatives, but because the Smad4 is the common Smad that is crucial for nuclear localization, an up-regulation of Smad2 or Smad3 in the Smad4 dominant-negative cell line would not alter signal transduction. In addition, overexpression of Smad3(D407E) hinders the phosphorylation of Smad2 by TGF-␤ type I receptor (33) .
A third explanation for the incomplete blockade by dominant-negative Smads of TGF-␤ stimulation of PTHrP production is that TGF-␤ signaling in breast cancer cells utilizes both Smad and Smad-independent signaling pathways. TGF-␤ can activate components of MAP kinase pathways, mainly JNK, ERK, and p38 pathways (50 -52) , and recent studies suggest that some effects of TGF-␤ on cancer cells are Smad-independent (53) . To test this third possibility, we screened a variety of protein kinase inhibitors for their effects on basal and TGF-␤-stimulated PTHrP production in the MDA-MB-231 parental cell line. Under the conditions tested, none of the inhibitors showed cellular toxicity or reduced cell numbers (data not shown). We found that only p38 MAP kinase inhibitors substantially reduced TGF-␤-stimulated PTHrP production, whereas MEK1/2 inhibition reduced basal PTHrP production in MDA-MB-231 cells. Other protein kinase inhibitors had no effect on PTHrP production.
Thus, the third explanation is the most likely. TGF-␤ stimulates PTHrP production through both Smad-dependent and MAP kinase signaling pathways. This explanation was also supported by using cell lines stably expressing dominant-negative Smads in combination with MAP kinase inhibitors (Fig.  5) . The combined inhibition of Smad and p38 MAP kinase signaling eliminated TGF-␤ stimulation of PTHrP production as effectively as the overexpression of dominant-negative TGF-␤ type II receptor. The MEK inhibitor reduced the basal PTHrP production in Smad dominant-negative clones to nearly undetectable concentrations. In addition, TGF-␤ increased the phosphorylation of p38 MAP kinase in a time-dependent fashion consistent with relevant MAP kinase activation (Fig. 6) , further supporting the role of p38 MAP kinase in TGF-␤-induced PTHrP production. The MAP kinase inhibitors had no additional effect on PTHrP production in the MDA-MB-231 clone overexpressing TGF-␤ dominant-negative type II receptor. These data indicate that the effects of TGF-␤ on MAP kinase pathways are mediated through the TGF-␤ receptor. The results suggest that MDA-MB-231 breast cancer cells use both Smad and MAP kinase pathways to regulate PTHrP production. There is also evidence for MAP kinase involvement in other indicators of the metastatic phenotype in MDA-MB-231 cells. For example, activated p38 MAP kinase is essential for matrix invasion by breast cancer cells such as MDA-MB-231 (54) . Similarly, both Smad and p38 MAP kinase pathways are activated by activin, a member of TGF-␤ gene family in the human breast cancer T47D cell line (55) .
Although the inhibitor SB203580 was originally reported to be highly specific for p38 (56) , the serine kinase activities of the TGF-␤ type I and II receptors can be inhibited weakly by the same compound (57) . Because 400 -800-fold higher concentrations of SB203580 are needed to inhibit TGF-␤ receptor activity compared with p38 activity (58), it is highly unlikely that the concentrations of SB203580 used in this study would be suffi- cient to directly inhibit the TGF-␤ receptor kinase. The other p38 inhibitor, SB202190, has been reported to induce apoptosis in Jurkat cells through inhibition of p38␤ MAP kinase (59) . However, no reductions of cell number in the SB202190-treated cells or in any other inhibitor-treated cells were observed after the pretreatment and 24 h of incubation when compared with the controls. Both compounds inhibit the p38␣ and ␤ isoforms but not the ␥ and ␦ isoforms (60, 61) . Whether TGF-␤ promotes PTHrP production via p38␣ or ␤ forms or both in MDA-MB-231 cells remains to be studied.
The interactions between MAP kinase and Smad signaling pathways downstream of the TGF-␤ receptor may be complex. Smad2 and Smad3 are direct substrates for phosphorylation by active type I receptor. Because none of three dominant-negative forms of these two proteins could fully suppress TGF-␤ responsiveness, activation of the p38 MAP kinase pathway must be consequent to activation of the TGF-␤ type I receptor but independent of Smads 2 and 3, as shown by the data in Fig.  5 . In addition, there are extensive examples of cross-talk between the Smad pathway and the ERK, JNK, and p38 MAP kinase pathways that could participate in the TGF-␤ signaling to increase PTHrP upstream of p38 kinase as well as regulating PTHrP production upstream of MEK kinase (18) . For example, TAK1 activates p38 kinase through MKK6 or MKK3 and JNK via MKK4. Because MKK4 can also activate p38, TAK1 could activate p38 via MKK4. The Smads can also integrate multiple signaling pathways and directly affect target gene expression in TGF-␤-activated cells (62) . We propose the following mechanism by which TGF-␤ promotes breast cancer osteolysis. Metastatic breast cancer cells in the bone microenvironment secrete PTHrP, which stimulates osteoclastic bone resorption by increasing osteoblastic expression of RANK ligand (65) . TGF-␤, released in active form from the mineralized bone matrix as a consequence of osteoclastic bone resorption, activates the TGF-␤ receptors on tumor cells, which signal via both Smad and MAP kinase pathways. TGF-␤ signaling further stimulates tumor production of PTHrP. This vicious cycle results in the bone destruction and morbidity associated with breast cancer. Identification of the molecular mechanisms responsible for osteolytic metastases is crucial in designing effective therapy for osteolytic metastases of cancer.
